Methods for detecting breast and ovarian cancer
CA 2497058 A1 · Owner: Yousef, George · Inventors: Yousef, George; Diamandis, Eleftherios P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Kallikrein 5 constitutes a novel biomarker for diagnosis treatment and , monitoring of breast and ovarian cancer. A method is provided for diagnosing and monitoring breast or ovarian cancer or a predisposition to breast or ovarian cancer, in a subject comprising detecting kallikrein 5 in a sample from the subject. Imaging methods, screening methods for test agents for inhibiting breast or ovarian cancer, and therapeutic applications based on kallikrein 5 are also described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 28, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 28, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 28, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.